# Postoperative Recurrence in Crohn’s Disease: Pathophysiology, Risk Stratification, and Management Strategies

## TL;DR

Crohn’s disease often recurs after surgery, and new strategies are being developed to better predict and manage this recurrence.

## Contribution

The paper reviews current understanding of postoperative recurrence mechanisms and evaluates evolving risk-stratified management strategies.

## Key findings

- Ileocecal resection rates for Crohn’s disease are 18.7%, 28.0%, and 39.5% at one, five, and ten years.
- Non-invasive tools like fecal calprotectin and imaging show promise in monitoring recurrence.
- Anti-TNF agents and Vedolizumab are more effective than conventional therapies in preventing recurrence.

## Abstract

Postoperative recurrence (POR) remains a significant challenge in Crohn’s disease (CD) management despite therapeutic advances. Contemporary data show ileocecal resection rates of 18.7%, 28.0%, and 39.5% at one, five, and ten years after diagnosis, with endoscopic recurrence occurring in 22.4–53% of patients within 18–36 months postoperatively. Current understanding of POR pathophysiology includes microbiota dysbiosis, mesenteric inflammation, immune dysregulation, and genetic factors, particularly NOD2 variants. Key risk factors comprehend smoking, penetrating or perianal disease, prior surgeries, and extensive small bowel involvement. The Rutgeerts score remains the endoscopic gold standard for assessing recurrence, though it has never been validated and modifications addressing modern anastomotic techniques have been proposed. Non-invasive monitoring strategies using fecal calprotectin, intestinal ultrasound, and magnetic resonance enterography demonstrate promising diagnostic performance and may reduce the burden of routine endoscopy. Anti-TNF agents and Vedolizumab show superior efficacy in preventing endoscopic recurrence compared to conventional therapies, while other advanced therapies like anti-JAKs, risankizumab and ustekinumab demonstrate potential benefit in postoperative prophylaxis. Management approaches have evolved toward risk-stratified strategies balancing systematic prophylaxis against endoscopy-driven therapy. While medical prophylaxis remains first-line for high-risk patients, the expanding therapeutic armamentarium and improved understanding of pathophysiologic mechanisms enable increasingly personalized postoperative care. Further research is needed to validate risk assessment tools, optimize timing and selection of prophylactic therapies, and define the role of emerging agents in reducing long-term disease burden.